Multicenter evaluation of the prostate health index to detect aggressive prostate cancer in biopsy Naïve men

Journal of Urology

Volumn 194, Issue 1, 2015, Pages 65-72

  De La Calle, Claire ^a   Patil, Dattatraya ^a   Wei, John T ^b   Scherr, Douglas S ^c   Sokoll, Lori ^d   Chan, Daniel W ^d   Siddiqui, Javed ^b   Mosquera, Juan Miguel ^c   Rubin, Mark A ^c   Sanda, Martin G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biopsy; nomograms; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; CANCER DIAGNOSIS; COHORT ANALYSIS; COMPARATIVE STUDY; DIAGNOSTIC TEST ACCURACY STUDY; GENITAL SYSTEM DISEASE ASSESSMENT; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; BIOPSY; BLOOD; CLINICAL TRIAL; EVALUATION STUDY; HEALTH STATUS INDICATOR; MATHEMATICAL PHENOMENA; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; HEALTH STATUS INDICATORS; HUMANS; MALE; MATHEMATICAL CONCEPTS; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84940653766     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.01.091     Document Type: Article

References (27)

1. American Cancer Society®: Prostate Cancer, 2014. Available at http://www.cancer.org/cancer/prostatecancer/detailedguide/index. Accessed June 8, 2014.
2. A.S. Glass, J.E. Cowan, M.J. Fuldeore, and et al. Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era Urology 82 2013 60
3. F.H. Schröder, J. Hugosson, M.J. Roobol, and et al. Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981
4. I.M. Thompson, D.K. Pauler, P.J. Goodman, and et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter N Engl J Med 350 2004 2239
5. S. Loeb, A. Vellekoop, H.U. Ahmed, and et al. Systematic review of complications of prostate biopsy Eur Urol 64 2013 876
6. A.R. Zlotta, and R.K. Nam To biopsy or not to biopsy - thou shall think twice Eur Urol 61 2012 1115
7. W.J. Catalona, A.W. Partin, M.G. Sanda, and et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range J Urol 185 2011 1650
8. W.J. Catalona, A.W. Partin, K.M. Slawin, and et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial JAMA 279 1998 1542
9. B.V. Le, C.R. Griffin, S. Loeb, and et al. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study J Urol 183 2010 1355
10. L.J. Sokoll, Y. Wang, Z. Feng, and et al. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study J Urol 180 2008 539
11. C. Stephan, K. Jung, A. Semjonow, and et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer Clin Chem 59 2013 280
12. X. Filella, and N. Gimenez Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis Clin Chem Lab Med 51 2013 729
13. D. Bruzzese, C. Mazzarella, M. Ferro, and et al. Prostate health index vs %free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: systematic review and meta-analysis Transl Res 164 2014 444
14. A. Abrate, M. Lazzeri, G. Lughezzani, and et al. Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMEtheuS project, a multicentre European prospective study BJU Int 115 2015 537
15. M. Lazzeri, A. Haese, A. de la Taille, and et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study Eur Urol 63 2013 986
16. L.J. Sokoll, D.W. Chan, G.G. Klee, and et al. Multi-center analytical performance evaluation of the Access Hybritech(R) p2PSA immunoassay Clin Chim Acta 413 2012 1279
17. G. Qin, Y.S. Hsu, and X.H. Zhou New confidence intervals for the difference between two sensitivities at a fixed level of specificity Stat Med 25 2006 3487
18. M. Gönen Analyzing Receiver Operating Characteristic Curves with SAS 2007 SAS Institute Cary, North Carolina
19. R.W. Platt, J.A. Hanley, and H. Yang Bootstrap confidence intervals for the sensitivity of a quantitative diagnostic test Stat Med 19 2000 313
20. M.S. Pepe The Statistical Evaluation of Medical Tests for Classification and Prediction 2003 Oxford University Press New York
21. X.H. Zhou, and G. Qin Improved confidence intervals for the sensitivity at a fixed level of specificity of a continuous-scale diagnostic test Stat Med 24 2005 465
22. H.B. Carter American Urological Association (AUA) guideline on prostate cancer detection: process and rationale BJU Int 112 2013 543
23. V.A. Moyer Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 157 2012 120
24. C. Stephan, A.M. Kahrs, H. Cammann, and et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases Prostate 69 2009 198
25. M. Ferro, D. Bruzzese, S. Perdona, and et al. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml PLoS One 8 2013 e67687
26. F.H. Jansen, R.H. van Schaik, J. Kurstjens, and et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection Eur Urol 57 2010 921
27. S. Loeb, M.G. Sanda, D.L. Broyles, and et al. The Prostate Health Index selectively identifies clinically significant prostate cancer J Urol 193 2015 1163